InvestorsHub Logo
Followers 155
Posts 2641
Boards Moderated 0
Alias Born 01/29/2004

Re: Steady_T post# 427430

Tuesday, 08/15/2023 5:23:02 PM

Tuesday, August 15, 2023 5:23:02 PM

Post# of 462085
Anavex/Missling Have the Strong Hand

The results you cite are very good in the rat model. I would call those results highly suggestive.


And so would many others, who don't really comprehend the ubiquity of the sigma-1 receptor in all vertebrates.

However, the biologists at any of the world's major pharmaceutical manufacturers, who have scrutinized all of the published literature on Anavex 3-71, don't share your perception that the lab-confirmed data are merely "suggestive." They can see and know that blarcamesine, alone, will change CNS therapies; once commercially available. But subsequent clinical studies, in humans, will authenticate Anavex 3-71's ultimate superiority.

All of that plays into the competitive viability of both existing and proposed new CNS therapies. In two or three years, all of this will be sorted out, revealed by the profound therapeutic successes of both Anavex drugs. Missling knows the strengths of his hand in this seminal CNS drug therapy game. It will allow him to cut deals and make arrangements very favorable to both Anavex Life Sciences Corp and its stockholders.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News